Pérez, Antonio
Redondo-Antón, Jennifer http://orcid.org/0000-0003-2661-5866
Romera, Irene
Lizán, Luís
Rubio-de Santos, Miriam
Díaz-Cerezo, Silvia
Orozco-Beltrán, Domingo
Funding for this research was provided by:
Lilly, S.A.U.
Article History
Received: 18 August 2023
Accepted: 23 October 2023
First Online: 22 November 2023
Declarations
:
: Antonio Pérez reports honoraria from Sanofi, Boehringer Ingelheim, Menarini, Novo Nordisk, Lilly, Pfizer, Amarin, Daiichi Sankyo, AstraZeneca, Almirall, Novartis, Merck Sharp & Dohme, Amgen, AMARIN and Esteve outside of the submitted work.Jennifer Redondo-Antón, Irene Romera, Miriam Rubio-de Santos and Silvia Díaz-Cerezo are employees and minor shareholders of Eli Lilly. Luis Lizán works for an independent scientific consultancy (Outcomes’10) that has received honoraria for conducting the systematic literature review and writing the manuscript for conducting the systematic literature review and manuscript writing tasks. Domingo Orozco-Beltrán reports honoraria from MSD, Lilly and Novo Nordisk outside of the submitted work.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.